Travere Therapeutics Q2 2024 Adj. EPS $(0.65) Beats $(0.86) Estimate, Sales $52.176M Beat $50.169M Estimate
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics (NASDAQ:TVTX) reported Q2 2024 adjusted EPS of $(0.65), beating the $(0.86) estimate. Sales were $52.176M, surpassing the $50.169M estimate. Despite a year-over-year sales decline, the results were better than expected.
August 01, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.65) beating the $(0.86) estimate and sales of $52.176M surpassing the $50.169M estimate. Despite a year-over-year sales decline, the positive earnings surprise is likely to boost investor sentiment.
The better-than-expected EPS and sales figures are likely to positively impact the stock price in the short term. Beating analyst estimates generally boosts investor confidence, despite the year-over-year sales decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100